Larimar Therapeutics (NASDAQ:LRMR) Announces Earnings Results

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) issued its earnings results on Monday. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.06, FiscalAI reports.

Larimar Therapeutics Stock Performance

Larimar Therapeutics stock opened at $3.02 on Monday. The firm has a market capitalization of $313.73 million, a price-to-earnings ratio of -1.55 and a beta of 0.73. Larimar Therapeutics has a fifty-two week low of $1.91 and a fifty-two week high of $6.42. The stock’s fifty day moving average is $2.93 and its two-hundred day moving average is $3.76.

Insider Transactions at Larimar Therapeutics

In other news, COO John B. Jr. Harlow purchased 17,800 shares of the business’s stock in a transaction dated Wednesday, November 11th. The stock was acquired at an average price of $2.80 per share, with a total value of $49,840.00. Following the purchase, the chief operating officer directly owned 67,800 shares of the company’s stock, valued at $189,840. This represents a 35.60% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Thomas Hamilton acquired 70,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $186,900.00. Following the completion of the transaction, the director directly owned 70,000 shares in the company, valued at approximately $186,900. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 140,810 shares of company stock worth $381,955. Corporate insiders own 4.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on LRMR shares. Wall Street Zen cut shares of Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, October 15th. Leerink Partners assumed coverage on shares of Larimar Therapeutics in a research report on Monday, September 14th. They set an “outperform” rating and a $13.00 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday, November 10th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $10.33.

Read Our Latest Stock Report on Larimar Therapeutics

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Read More

Earnings History for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.